Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Highlights Launches, Late-State Pipeline To Distract From Sluggish Earnings

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Ian Read admitted tax inversion remains an attractive potential deal-driver for now, though he declined to offer much insight into the company’s near-term M&A strategy.

You may also be interested in...



Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon

Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.

Health And Wellness Weekly Trademark Review 20 July, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Related Companies

UsernamePublicRestriction

Register

PS077819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel